Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects
Despite considerable improvements in the last two decades, chemotherapy-induced nausea and vomiting (CINV) remains a frequent and very bothersome medical problem. It is estimated that about one half to two thirds of all chemotherapy-treated patients experience CINV, the frequency depending on the ch...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2007-06-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/244 |
| _version_ | 1818676158422581248 |
|---|---|
| author | Lorenzo Pradelli Mario Eandi |
| author_facet | Lorenzo Pradelli Mario Eandi |
| author_sort | Lorenzo Pradelli |
| collection | DOAJ |
| description | Despite considerable improvements in the last two decades, chemotherapy-induced nausea and vomiting (CINV) remains a frequent and very bothersome medical problem. It is estimated that about one half to two thirds of all chemotherapy-treated patients experience CINV, the frequency depending on the chemotherapy regimen used and on patient-specific features. The impact of CINV, which may be acute, delayed or even anticipatory in experienced patients, on health-related quality of life (HRQoL) is substantial in all domains.
Until recently, effective treatment choices included corticosteroids and first-generation 5-HT3 antagonists, which have been supported by aprepitant, the first clinically available NK1 antagonist, and by palonosetron, considered the first second-generation 5-HT3 antagonist for its high receptor-subtype selectivity and affinity and long plasmatic half-life. In this paper, clinical pharmacology of the latter drug is briefly outlined and recent Italian papers on the epidemiology and HRQoL impact of CINV are reviewed, as well as national pharmacoeconomic evalutations conducted on palonosetron. The role in therapy of palonosteron and its potential for improved clinical, HRQoL and economic outcomes is discussed. |
| first_indexed | 2024-12-17T08:39:02Z |
| format | Article |
| id | doaj.art-8f50375229814df08b09bb908363bc28 |
| institution | Directory Open Access Journal |
| issn | 2240-256X |
| language | English |
| last_indexed | 2024-12-17T08:39:02Z |
| publishDate | 2007-06-01 |
| publisher | SEEd Medical Publishers |
| record_format | Article |
| series | Farmeconomia: Health Economics and Therapeutic Pathways |
| spelling | doaj.art-8f50375229814df08b09bb908363bc282022-12-21T21:56:23ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2007-06-0182718010.7175/fe.v8i2.244219Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspectsLorenzo Pradelli0Mario Eandi1Centro di ricerche farmacoeconomiche, Advanced Research srl, Torino
Dipartimento di Farmacologia clinica, Università di TorinoDespite considerable improvements in the last two decades, chemotherapy-induced nausea and vomiting (CINV) remains a frequent and very bothersome medical problem. It is estimated that about one half to two thirds of all chemotherapy-treated patients experience CINV, the frequency depending on the chemotherapy regimen used and on patient-specific features. The impact of CINV, which may be acute, delayed or even anticipatory in experienced patients, on health-related quality of life (HRQoL) is substantial in all domains.
Until recently, effective treatment choices included corticosteroids and first-generation 5-HT3 antagonists, which have been supported by aprepitant, the first clinically available NK1 antagonist, and by palonosetron, considered the first second-generation 5-HT3 antagonist for its high receptor-subtype selectivity and affinity and long plasmatic half-life. In this paper, clinical pharmacology of the latter drug is briefly outlined and recent Italian papers on the epidemiology and HRQoL impact of CINV are reviewed, as well as national pharmacoeconomic evalutations conducted on palonosetron. The role in therapy of palonosteron and its potential for improved clinical, HRQoL and economic outcomes is discussed.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/244chemotherapy-induced nausea and vomiting (cinv)hrqolpalonosetron |
| spellingShingle | Lorenzo Pradelli Mario Eandi Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects Farmeconomia: Health Economics and Therapeutic Pathways chemotherapy-induced nausea and vomiting (cinv) hrqol palonosetron |
| title | Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects |
| title_full | Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects |
| title_fullStr | Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects |
| title_full_unstemmed | Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects |
| title_short | Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects |
| title_sort | palonosetron in the prevention of chemotherapy induced nausea and vomiting in italy pharmacoeconomic and clinical aspects |
| topic | chemotherapy-induced nausea and vomiting (cinv) hrqol palonosetron |
| url | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/244 |
| work_keys_str_mv | AT lorenzopradelli palonosetroninthepreventionofchemotherapyinducednauseaandvomitinginitalypharmacoeconomicandclinicalaspects AT marioeandi palonosetroninthepreventionofchemotherapyinducednauseaandvomitinginitalypharmacoeconomicandclinicalaspects |